Why GlaxoSmithKline Plc Excites Investors Like Me

A recent news item that you may have missed makes me feel very excited about investing in GlaxoSmithKline plc (LON: GSK)

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always fascinated by developments in science and medicine. Indeed, although I do not have a background in either field, I have first-hand experience of the wonders of drugs and various treatments. I’m amazed at how such areas have improved during my lifetime.

So, news that the prospect of using electric implants to treat a wide range of diseases (including arthritis) has taken a big step closer to reality is great news for the world and also great news for investors in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

This is because GlaxoSmithKline has launched a $50mn venture capital fund to “invest in companies that pioneer bioelectronic medicines and technologies”. The company will also build-up its own research expertise in this area, which is good news for shareholders.

Indeed, GlaxoSmithKline is aiming to have the first medicine that “speaks the electronic language of our body” ready within a decade. This is really exciting news, not just for patients, but for shareholders in GlaxoSmithKline as well.

The reason this is good news is that the company continues to push the boundaries of research and development and, in doing so, puts itself in a hugely coveted position as one of the world’s leaders in this field. Doing so increases the barriers to entry to the industry, equating to higher margins and profits for shareholders like me.

In addition to the above developments, GlaxoSmithKline remains one of my favoured income plays. It currently offers a yield of 4.4% and trades on a price-to-earnings ratio of 14.8, which — when compared to the FTSE 100 on 15.1 and the healthcare sector on 17.5 — looks very good value indeed.

Furthermore, shares are forecast to grow at an annualised rate of around 6% over the next two years. While this is not mind-blowing, it’s steady and very achievable.

Although a yield of 4.4% is twice as good as anything you can get from a savings account, you may wish to look at another high-yielding stock. It’s best described as The Motley Fool’s Top Income Share Of 2013.

I’d recommend you take a look by clicking here – it’s completely free to do so!

> Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »